Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6

Figure 1 Ectonucleoside triphosphate diphosphohydrolase 6 expressions in pan-cancer. A: Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) expression levels both in the tumor and normal tissues from The Cancer Genome Atlas dataset; B: ENTPD6 expression levels in the paired tumor/normal samples of the datasets from The Cancer Genome Atlas and Genotype-Tissue Expression databases; C: Subcellular localization of ENTPD6 in SK-MEL-30 cell line from The Human Protein Atlas database, scale bar: 20 μm. Red, green, and blue represent microtubules, the target protein, and the nucleus, respectively; D and E: The association between ENTPD6 expression and pathological stages in head and neck squamous cell carcinoma and uveal melanoma; F-J: ENTPD6 expression correlated with tumor grades in bladder urothelial carcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and stomach adenocarcinoma. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. ENTPD6: Ectonucleoside triphosphate diphosphohydrolase 6; TPM: Transcripts per million; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression; HNSC: Head and neck squamous cell carcinoma; UVM: Uveal melanoma; BLCA: Bladder urothelial carcinoma; KIRC: Kidney renal clear cell carcinoma; LIHC: Liver hepatocellular carcinoma; STAD: Stomach adenocarcinoma.